Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It's Apples Versus Oranges in the PI3 Kinase Race

This article was originally published in Start Up

Executive Summary

Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.
Advertisement

Related Content

Paloma Pharmaceuticals Inc.
Intellikine Inc.
Start-Up Previews (10/2009)
Arno Therapeutics
Intellikine Inc.
Arno Therapeutics
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Calistoga Pharmaceuticals Inc.
Calistoga Pharmaceuticals Inc.

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel